RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Human Metabolome Technologies Stock

Human Metabolome Technologies Net Income 2024

Human Metabolome Technologies Net Income

243.25 M JPY

Ticker

6090.T

ISIN

JP3794530000

In 2024, Human Metabolome Technologies's profit amounted to 243.25 M JPY, a -14.88% increase from the 285.76 M JPY profit recorded in the previous year.

The Human Metabolome Technologies Net Income history

YEARNET INCOME (undefined JPY)
2026e270.51
2025e232.99
2024243.25
2023285.76
2022267.79
202158.21
2020-47.79
2019-596.03
2018-156.53
2017-61.91
2016-71.47
2015-34.73
20141.6
2013-95.3
2012-46.4
201175.4
2010-39.8
2009-275.3

Human Metabolome Technologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Human Metabolome Technologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Human Metabolome Technologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Human Metabolome Technologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Human Metabolome Technologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Human Metabolome Technologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Human Metabolome Technologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Human Metabolome Technologies’s growth potential.

Human Metabolome Technologies Revenue, EBIT and net profit per share

DateHuman Metabolome Technologies RevenueHuman Metabolome Technologies EBITHuman Metabolome Technologies Net Income
2026e1.48 B undefined0 undefined270.51 M undefined
2025e1.46 B undefined0 undefined232.99 M undefined
20241.35 B undefined220.17 M undefined243.25 M undefined
20231.3 B undefined210.98 M undefined285.76 M undefined
20221.22 B undefined191.15 M undefined267.79 M undefined
20211.12 B undefined39.37 M undefined58.21 M undefined
20201.12 B undefined-17.04 M undefined-47.79 M undefined
2019989.39 M undefined-526.18 M undefined-596.03 M undefined
2018938.18 M undefined-140.91 M undefined-156.53 M undefined
2017914.18 M undefined-43.33 M undefined-61.91 M undefined
2016780.38 M undefined-70.36 M undefined-71.47 M undefined
2015686.62 M undefined-100.51 M undefined-34.73 M undefined
2014610.4 M undefined-12.3 M undefined1.6 M undefined
2013496.3 M undefined-104.8 M undefined-95.3 M undefined
2012522 M undefined-106.1 M undefined-46.4 M undefined
2011568.9 M undefined26.4 M undefined75.4 M undefined
2010380.7 M undefined-40.5 M undefined-39.8 M undefined
2009246 M undefined-195.5 M undefined-275.3 M undefined

Human Metabolome Technologies stock margins

The Human Metabolome Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Human Metabolome Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Human Metabolome Technologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Human Metabolome Technologies's sales revenue. A higher gross margin percentage indicates that the Human Metabolome Technologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Human Metabolome Technologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Human Metabolome Technologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Human Metabolome Technologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Human Metabolome Technologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Human Metabolome Technologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Human Metabolome Technologies Margin History

Human Metabolome Technologies Gross marginHuman Metabolome Technologies Profit marginHuman Metabolome Technologies EBIT marginHuman Metabolome Technologies Profit margin
2026e64.6 %0 %18.29 %
2025e64.6 %0 %16 %
202464.6 %16.36 %18.08 %
202366.17 %16.24 %21.99 %
202268.67 %15.63 %21.89 %
202171.71 %3.5 %5.18 %
202076.6 %-1.52 %-4.27 %
201967.99 %-53.18 %-60.24 %
201879.14 %-15.02 %-16.68 %
201779.75 %-4.74 %-6.77 %
201673.13 %-9.02 %-9.16 %
201567.89 %-14.64 %-5.06 %
201467.5 %-2.02 %0.26 %
201359.24 %-21.12 %-19.2 %
201270.63 %-20.33 %-8.89 %
201171.28 %4.64 %13.25 %
201067.45 %-10.64 %-10.45 %
200959.88 %-79.47 %-111.91 %

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Human Metabolome Technologies's Profit Margins

The profit margins of Human Metabolome Technologies represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Human Metabolome Technologies's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Human Metabolome Technologies's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Human Metabolome Technologies's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Human Metabolome Technologies’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Human Metabolome Technologies stock

How much profit has Human Metabolome Technologies made this year?

Human Metabolome Technologies has made 243.25 M JPY this year.

How has the profit developed compared to last year?

The profit has increased by -14.88% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Human Metabolome Technologies publish its earnings?

Human Metabolome Technologies publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Human Metabolome Technologies?

The profits of Human Metabolome Technologies are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Human Metabolome Technologies?

You can learn more about the earnings of Human Metabolome Technologies by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 15 JPY . This corresponds to a dividend yield of about 2.48 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 15 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 2.48 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 15 JPY are expected. This corresponds to a dividend yield of 2.48 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 10 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Human Metabolome Technologies

Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.